Tags

Type your tag names separated by a space and hit enter

Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
Int J Gynaecol Obstet. 2004 Oct; 87(1):29-33.IJ

Abstract

OBJECTIVES

To compare the clinical and hormonal effects of finasteride and a combination regimen of cyproterone acetate (CPA) plus ethinyl estradiol (EE2) in the treatment of hirsutism.

METHODS

Forty hirsute women were enrolled in a prospective randomized trial. Twenty-nine had polycystic ovary syndrome (PCOS) and 11 had idiopathic hirsutism. Patients were randomly treated with finasteride (5 mg/day; n=20) or CPA plus EE2 [CPA (25 mg/day on days 5-14) plus EE2 (20 microg/day on days 5-25) n=20] for 9 months. Main outcome measurement was a reduction in hair growth. Hirsutism score and hormone levels were measured at the beginning and at the end of the study. The student t-test and Mann-Whitney U tests were used for analysis of the data.

RESULTS

The modified Ferriman-Gallwey scores for hirsutism decreased significantly at the end of the study from a mean+/-SD of 23.7+/-4.4 to 11.3+/-1.5; P=<0.001 in finasteride group and from 22.3+/-4.2 to 11.4+/-1.2; P=<0.001 in CPA plus EE2 group. Improvement of hirsutism induced by the two treatment methods was similar (47.6 % vs. 51.1%; P=0.2). Treatment with CPA plus EE2 significantly decreased serum total and free T, A, DHEAS, and DHT and increased SHBG levels. Finasteride significantly increased total T but reduced DHT levels.

CONCLUSION

Finasteride and CPA plus EE2 are equally effective in decreasing hirsutism, despite significantly different effects on serum hormone levels.

Authors+Show Affiliations

Beigi A
Department of Obstetrics and Gynecology, Arash Maternity Hospital, Tehran University of Medical Sciences, Tehran, Iran. beigi_a@yahoo.com
Sobhi A
No affiliation info available
Zarrinkoub F
No affiliation info available

MeSH

AdolescentAdultAndrogen AntagonistsCyproterone AcetateEnzyme InhibitorsEthinyl EstradiolFemaleFinasterideHirsutismHumansPolycystic Ovary SyndromeProspective Studies

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15464773

Citation

Beigi, A, et al. "Finasteride Versus Cyproterone Acetate-estrogen Regimens in the Treatment of Hirsutism." International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, vol. 87, no. 1, 2004, pp. 29-33.
Beigi A, Sobhi A, Zarrinkoub F. Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Int J Gynaecol Obstet. 2004;87(1):29-33.
Beigi, A., Sobhi, A., & Zarrinkoub, F. (2004). Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, 87(1), 29-33.
Beigi A, Sobhi A, Zarrinkoub F. Finasteride Versus Cyproterone Acetate-estrogen Regimens in the Treatment of Hirsutism. Int J Gynaecol Obstet. 2004;87(1):29-33. PubMed PMID: 15464773.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. AU - Beigi,A, AU - Sobhi,A, AU - Zarrinkoub,F, PY - 2004/03/12/received PY - 2004/06/03/revised PY - 2004/06/07/accepted PY - 2004/10/7/pubmed PY - 2004/12/22/medline PY - 2004/10/7/entrez SP - 29 EP - 33 JF - International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics JO - Int J Gynaecol Obstet VL - 87 IS - 1 N2 - OBJECTIVES: To compare the clinical and hormonal effects of finasteride and a combination regimen of cyproterone acetate (CPA) plus ethinyl estradiol (EE2) in the treatment of hirsutism. METHODS: Forty hirsute women were enrolled in a prospective randomized trial. Twenty-nine had polycystic ovary syndrome (PCOS) and 11 had idiopathic hirsutism. Patients were randomly treated with finasteride (5 mg/day; n=20) or CPA plus EE2 [CPA (25 mg/day on days 5-14) plus EE2 (20 microg/day on days 5-25) n=20] for 9 months. Main outcome measurement was a reduction in hair growth. Hirsutism score and hormone levels were measured at the beginning and at the end of the study. The student t-test and Mann-Whitney U tests were used for analysis of the data. RESULTS: The modified Ferriman-Gallwey scores for hirsutism decreased significantly at the end of the study from a mean+/-SD of 23.7+/-4.4 to 11.3+/-1.5; P=<0.001 in finasteride group and from 22.3+/-4.2 to 11.4+/-1.2; P=<0.001 in CPA plus EE2 group. Improvement of hirsutism induced by the two treatment methods was similar (47.6 % vs. 51.1%; P=0.2). Treatment with CPA plus EE2 significantly decreased serum total and free T, A, DHEAS, and DHT and increased SHBG levels. Finasteride significantly increased total T but reduced DHT levels. CONCLUSION: Finasteride and CPA plus EE2 are equally effective in decreasing hirsutism, despite significantly different effects on serum hormone levels. SN - 0020-7292 UR - https://www.unboundmedicine.com/medline/citation/15464773/Finasteride_versus_cyproterone_acetate_estrogen_regimens_in_the_treatment_of_hirsutism_ DB - PRIME DP - Unbound Medicine ER -